SCHEMBL1126285 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	RAB9A	P51151	3/20	0.38

▸	NPC1	O15118	2/20	0.38

▸	MAOB	P27338	1/20	0.38

▸	FGFR1	P11362	2/20	0.37

▸	CYP1A1	P04798	3/20	0.37

▸	CYP1B1	Q16678	3/20	0.37

▸	CYP1A2	P05177	1/20	0.37

▸	CYP2E1	P05181	1/20	0.37

▸	CYP3A4	P08684	1/20	0.37

▸	CYP2C8	P10632	1/20	0.37

▸	CYP2D6	P10635	1/20	0.37

▸	CYP2A6	P11509	1/20	0.37

▸	CYP2C9	P11712	1/20	0.37

▸	CYP4B1	P13584	1/20	0.37

▸	CYP2B6	P20813	1/20	0.37

▸	CYP3A5	P20815	1/20	0.37

▸	CYP2A7	P20853	1/20	0.37

▸	CYP3A7	P24462	1/20	0.37

▸	CYP2F1	P24903	1/20	0.37

▸	CYP2C18	P33260	1/20	0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL1126228	0.94	RAB9A (0.38)	RAB9ANPC1MAOBFGFR1CYP1A1
SCHEMBL14212761	0.93	MAOB (0.38)	RAB9ANPC1MAOBFGFR1CYP1A1
SCHEMBL14212767	0.88	MAOB (0.38)	RAB9ANPC1MAOBFGFR1CYP1A1
SCHEMBL1126107	0.85	FGFR1 (0.39)	RAB9ANPC1MAOBFGFR1CYP1A1
SCHEMBL13626925	0.83	ABL1 (0.40)	RAB9ANPC1FGFR1CYP1A1CYP1B1
SCHEMBL1126202	0.82	NQO2 (0.42)	RAB9ANPC1MAOBCYP1A1CYP1B1
SCHEMBL1126236	0.81	CYP1A1 (0.41)	RAB9ANPC1MAOBFGFR1CYP1A1
SCHEMBL14212775	0.81	MAOB (0.37)	RAB9ANPC1MAOBFGFR1CYP3A4
SCHEMBL13626928	0.81	ABL1 (0.40)	RAB9ANPC1FGFR1CYP1A1CYP1B1
SCHEMBL1126354	0.80	CYP11B1 (0.40)	RAB9ANPC1FGFR1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-2282995-B1	DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS	NOVARTIS AG (CH)	2015-08-26	—	—	EP	disclosed
EP-2282995-B1	DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS	NOVARTIS AG (CH)	2015-08-26	—	—	EP	disclosed
US-8815901-B2	Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors	NOVARTIS AG (CH)	2014-08-26	—	—	US	disclosed
US-8815901-B2	Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors	NOVARTIS AG (CH)	2014-08-26	—	—	US	disclosed
US-8674099-B2	Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors	NOVARTIS AG (CH)	2014-03-18	—	—	US	disclosed
US-8674099-B2	Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors	NOVARTIS AG (CH)	2014-03-18	—	—	US	disclosed
US-20130324519-A1	QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS	NOVARTIS AG (CH)	2013-12-05	—	—	US	disclosed
US-8536175-B2	Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors	NOVARTIS AG (CH)	2013-09-17	—	—	US	disclosed
US-8536175-B2	Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors	NOVARTIS AG (CH)	2013-09-17	—	—	US	disclosed
CN-102036963-B	Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors	NOVARTIS AG	2013-08-21	—	—	CN	disclosed
US-20120309766-A1	QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS	NOVARTIS AG (CH)	2012-12-06	—	—	US	disclosed
US-8273882-B2	Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors	NOVARTIS AG (CH)	2012-09-25	—	—	US	disclosed
US-8273882-B2	Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors	NOVARTIS AG (CH)	2012-09-25	—	—	US	disclosed
US-8273882-B2	Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors	NOVARTIS AG (CH)	2012-09-25	—	—	US	disclosed
CN-102036963-A	Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors	NOVARTIS AG	2011-04-27	—	—	CN	disclosed
EP-2282995-A1	DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS	Novartis AG (CH)	2011-02-16	—	—	EP	disclosed
US-20100105667-A1	Quinoxaline- and Quinoline-Carboxamide Derivatives	NOVARTIS AG	2010-04-29	—	—	US	disclosed
US-20100105667-A1	Quinoxaline- and Quinoline-Carboxamide Derivatives	NOVARTIS AG	2010-04-29	—	—	US	disclosed
US-20100105667-A1	Quinoxaline- and Quinoline-Carboxamide Derivatives	NOVARTIS AG	2010-04-29	—	—	US	disclosed
WO-2009141386-A1	DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS	NOVARTIS AG (CH)	2009-11-26	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100105667-A1	Quinoxaline- and Quinoline-Carboxamide Derivatives	ABL1, NQO2, MAP4K5	RAB9A 1249/4885NPC1 2473/4885MAOB 373/4885
US-20130324519-A1	QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS	ABL1, BTK, PDXK	RAB9A 1177/4885NPC1 3827/4885MAOB 418/4885
US-20120309766-A1	QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS	ABL1, BTK, PDXK	RAB9A 1177/4885NPC1 3827/4885MAOB 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.